Global Cloud Based Drug Discovery Platforms Market Overview

The Global Cloud-Based Drug Discovery Platforms Market size is expected to grow from USD 2.22 Billion in 2022 to USD 5.04 Billion by 2030, at a CAGR of 10.8% during the forecast period (2023-2030).

Cloud computing technology gives customers access to storage, files, software, and servers through internet-connected devices such as computers, smartphones, tablets, and wearables. Cloud computing solution providers store and process data in a location that's separate from end-users. Moreover, cloud computing provides the ability to store and access data and programs over the internet instead of on a hard drive. The usage of cloud-based drug discovery platforms in pharmaceutical and biotechnology firms allows collaboration with scientists and companies around the world.  Furthermore, cloud-based drug discovery platforms reduce the risk and accelerate the drug development process by utilizing cost-effective, high-performance computing power and Artificial Intelligence/Machine Learning capabilities on the extensive cloud infrastructure. Additionally, cloud-based platforms assure secure research collaborations between different global teams and simplify data movement from lab equipment to integrate research environments. Cloud-based platforms provide the user with large storage options that aid in optimizing costs and performance. According to a study published in the Journal of the American Medical Association, the median cost of bringing a new drug to market is estimated to be $985 million, and the average cost is $1.3 billion. With the incorporation of cloud-based drug discovery platforms, the cost of drug discovery can be reduced thus, supporting the expansion of the market during the forecast period.

Market Dynamics And Key Factors In Cloud Based Drug Discovery Platforms Market

Drivers:

With cloud-based drug discovery platforms, an individual with an internet connection and proper security codes can participate in the drug discovery process irrespective of its geographic location. Additionally, it enables researchers globally, not only from different departments but also different companies with different processes and cultures, to collaborate and exchange data and function as a team in the drug discovery process. Moreover, with the adoption of cloud-based platforms, it became effortless for research institutions to organize several different drug discovery projects without having to upload all the information repeatedly. The data generated by the pharmaceutical companies is enormous and its management is a critical issue. Additionally, pharmaceutical companies are utilizing cloud-based drug discovery platforms to bolster their drug development process and to manage the huge data generated. Furthermore, storing data on clouds not only offers cost-saving but also improves accessibility thus, strengthening the development of cloud-based drug discovery platforms in the forecast period.

Zero lag time is the unique feature offered by the cloud-based drug discovery platform, which saves time and gives real-time access to users. Moreover, by employing cloud computing, the collection of data from appropriate individuals participating in clinical trials, across the globe can be done in real-time thereby, reducing the complexity of data collection. Furthermore, global pharma companies can leverage cloud solutions from any remote locations to suit a localized workforce, and the cost incurred in conducting clinical trials by developing exclusive data centers can be eliminated. Cloud-based high-performance computing aids Research and Development teams to access computational resources and along with Artificial and Machine Learning technologies, the cloud can accelerate the processes leading to faster release of the drug.  Researchers will benefit from the automation of data processes coupled with other digital technologies like biosensors thus, driving the growth of the cloud-based drug discovery platforms in the estimated period.

Restraints:

The main concern while deploying a cloud-based system in research organizations is the security of the data. Moreover, the rising incidences of cyber breaches and lack of information systems control are the main factors hampering the expansion of cloud-based drug discovery platforms growth in the forecast period. Furthermore, to access the data stored in the cloud, research institutions or individuals require reliable internet connectivity. Without a secure internet connection, the data stored on the cloud is not accessed. Vendor lock-in is the main disadvantage of cloud computing. Pharma industries may face problems while transferring services from one vendor to another. As different vendors provide different platforms, that can cause difficulty moving from one cloud to another thus, hindering the development of cloud-based drug discovery platforms during the projected period.

Opportunities:

The growing healthcare industry and the rise in the fundings for R&D activities to develop new drugs to treat diseases efficiently are creating better opportunities for software vendors. In recent years there has been a significant increase in the price of bringing new drugs to market, with estimates putting the cost as high as $1bn. This situation has forced R&D laboratories to turn to new laboratory informatics technologies, to reduce spending and launch essential drugs in the market, faster. With the adoption of cloud-based drug discovery platforms, institutions can cut down the time required to discover new drugs. Moreover, the rise in the number of research institutions and the growing biotechnology industry is generating lucrative opportunities for market players to develop robust software and meet all the requirements of the users.

Market Segmentation

Segmentation Analysis of Cloud Based Drug Discovery Platforms Market:

Depending on the type, Software as a service (SaaS) segment is expected to dominate the cloud-based drug discovery platforms market in the projected period. SaaS reduced the time spent on the installation and configuration of software. The maintenance cost of SaaS is low as compared to other types thus, allowing access to small research organizations for cloud-based. SaaS can quickly and efficiently deliver the principal value of the clinical research application with the ability to capture, manage, share efficiently and effectively across thousands of investigators around the globe and among all stakeholders will help decrease the time for the whole clinical research cycle thus, driving the growth of this segment.

Depending on deployment mode, the hybrid segment is projected to lead the market over the estimated period attributed to the increase in the number of users, and resource mobility. In addition, the rapid migration of applications over the cloud, and the emergence of more sophisticated threats are prompting businesses to adopt hybrid cloud-based solutions. Pharmaceutical industries are adopting hybrid cloud solutions to support the migration of on-premise data and application workloads into the cloud, with objectives such as reducing costs, increasing IT efficiency, and reducing time-to-market for new drugs thus, driving the growth of this segment in the forecast period.

Depending on the end-user, the pharmaceutical vendor segment is expected to dominate the cloud-based drug discovery platforms market in the estimated period. The rise in the number of software vendors providing cloud-based drug discovery platforms to facilitate research and development processes is the main driving force for the growth of this segment. Moreover, to tackle new strains of viruses, bacteria, and to find appropriate medications on these outbreaks cloud-based platforms are aiding research organizations to develop drugs in a short time. Furthermore, the cost involved in traditional clinical trials can be reduced and the data generated while conducting clinical trials can be efficiently managed through cloud-based solutions thus, strengthening the expansion of the cloud-based drug discovery platforms market in the projected period.

Regional Analysis of Cloud Based Drug Discovery Platforms Market:

The North American region is expected to have the highest share of cloud-based drug discovery platforms in the forecast period. The growing number of pharmaceutical firms and a need to manage the huge data generated by this industry is the main factor driving the expansion of cloud-based drug discovery platforms in this region. Moreover, countries such as US and Canada have a wide presence of prominent cloud computing service providers. The growing prevalence of diseases and to find effective drugs quicker is stimulating pharmaceutical and biotechnology vendors to adopt cloud-based drug discovery platforms.

The European region is anticipated to have the second-highest share of the market during the projected period. The technological advancements in this region are promoting research institutes in this region to incorporate cloud-based drug discovery platforms to accelerate the drug development process. Key players in this region are offering flexible, cost-effective, and highly secure cloud-based storage options to users thereby, fueling the development of cloud-based drug discovery platforms.

The Asia-Pacific region is forecasted to expand at the highest growth rate. The rise in collaborations with a top western research organization and the growing inclination towards solutions offered by cloud-based services is promoting the progress of cloud-based drug discovery platforms in this region. China, Japan, and India are the major countries contributing to the growth of cloud-based drug discovery platforms in this region.

Players Covered in Cloud Based Drug Discovery Platforms Market are:

• Accenture PLC (Ireland)
• Acelot Inc (US)
• Cloud Pharmaceuticals Inc. (US)
• Dassault Systemes (France)
• IBM Corporation (US)
• SAS Institute Inc. (the US)
• Tata Consultancy Services Ltd. (India)
• WuXi AppTec (China)
• Collaborative Drug Discovery (CDD)
• SCYNEXIS Inc. (the US)
• Medidata (US)
• Certara (US)
• Google (US)
• Cloudpharm
• Amazon Web Services Inc. (US) and other major players.

COVID-19 Impact on Cloud Based Drug Discovery Platforms Market

With the outbreak of the COVID-19 pandemic, several industry verticals were forced to shut down their operational activities. Moreover, to constraint the spread of the virus the number of workers, working in the pharmaceutical and biotechnology industry were reduced. In addition, the restrictions on transportation disrupted the supply chain of various pharmaceutical drugs. To overcome the financial losses incurred by the COVID-19 pandemic, many industry verticals started fundamentally leveraging cloud computing for their digital transformation process, pharmaceutical and biotechnology organizations started utilizing it for drug discovery and other critical processes. Furthermore, the pandemic has accelerated the adoption rate of cloud computing solutions by the pharma sector, which was slow in transitioning to the cloud earlier. According to a survey report published by Healthcare Information and Management Systems Society, more than 83 percent of pharma companies are already leveraging cloud services. With the Covid-19 pandemic driving innovation, the pharmaceutical industry is making headway in developing vaccines, repurposing drugs, and new drug discoveries to curb the spread of the virus. Huge investments are being made in Research and Development with the cloud becoming a key solution to streamline all IT expenses by reducing costs and increasing efficiency. In addition, to Research and Development activities, the subsequent development of the COVID-19 vaccine in a short period of one and half year demonstrated the vital contribution of cloud technology in advancing the process. Apart from drug development, big data is being leveraged to determine the effective dosage of various drugs through collating and interpreting scores of data points collected on a real-time basis.

Key Industry Developments In Cloud Based Drug Discovery Platforms Market

• In October 2021, Medidata declared the launch of its product Medidata sensor cloud network at NEXT Global 2021. With this Medidata sensor cloud network, contract research organizations (CROs), analytics companies, device manufacturers, drug and vaccine developers, and academia will be able to collaborate and solve challenges associated with sensor integrations, standardization of sensor data, and the development of digital biomarkers and algorithms.
• In October 2021, Certara, Inc. a global leader in biosimulation, declared the acquisition of Pinnacle 21, a prominent service provider of SaaS solutions for clinical data fitness, regulatory compliance, and submission readiness. This acquisition is expected to boost Certara's ability to address vital decisions that further de-risk and accelerate the drug development process. 
• In March 2021, Cleveland Clinic and IBM have entered a strategic 10-year collaboration to establish the Discovery Accelerator, a joint Cleveland Clinic - IBM center. This joint venture is formed to enhance the pace of drug discovery in healthcare and life sciences through the usage of high-performance computing on the hybrid cloud, artificial intelligence (AI), and quantum computing technologies.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Type
 3.2 By Deployment Mode
 3.3 By End User

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  3.5.1 Drivers
  3.5.2 Restraints
  3.5.3 Opportunities
  3.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 4: Cloud-Based Drug Discovery Platforms Market by Type
 4.1 Cloud-Based Drug Discovery Platforms Market Overview Snapshot and Growth Engine
 4.2 Cloud-Based Drug Discovery Platforms Market Overview
 4.3 Infrastructure as a Service {IaaS}
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size (2016-2028F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Infrastructure as a Service {IaaS}: Grographic Segmentation
 4.4 Software as a Service {SaaS}
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size (2016-2028F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Software as a Service {SaaS}: Grographic Segmentation
 4.5 Platform as a Service {PaaS}
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size (2016-2028F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Platform as a Service {PaaS}: Grographic Segmentation

Chapter 5: Cloud-Based Drug Discovery Platforms Market by Deployment Mode
 5.1 Cloud-Based Drug Discovery Platforms Market Overview Snapshot and Growth Engine
 5.2 Cloud-Based Drug Discovery Platforms Market Overview
 5.3 Public
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Public: Grographic Segmentation
 5.4 Private
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Private: Grographic Segmentation
 5.5 Hybrid
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Hybrid: Grographic Segmentation

Chapter 6: Cloud-Based Drug Discovery Platforms Market by End User
 6.1 Cloud-Based Drug Discovery Platforms Market Overview Snapshot and Growth Engine
 6.2 Cloud-Based Drug Discovery Platforms Market Overview
 6.3 Pharmaceutical Vendors
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Pharmaceutical Vendors: Grographic Segmentation
 6.4 Biotech Vendors
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Biotech Vendors: Grographic Segmentation
 6.5 Contract Research Organizations
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Contract Research Organizations: Grographic Segmentation
 6.6 Others
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Others: Grographic Segmentation

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Positioning
  7.1.2 Cloud-Based Drug Discovery Platforms Sales and Market Share By Players
  7.1.3 Industry BCG Matrix
  7.1.4 Ansoff Matrix
  7.1.5 Cloud-Based Drug Discovery Platforms Industry Concentration Ratio (CR5 and HHI)
  7.1.6 Top 5 Cloud-Based Drug Discovery Platforms Players Market Share
  7.1.7 Mergers and Acquisitions
  7.1.8 Business Strategies By Top Players
 7.2 ACCENTURE PLC (IRELAND)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Operating Business Segments
  7.2.5 Product Portfolio
  7.2.6 Business Performance
  7.2.7 Key Strategic Moves and Recent Developments
  7.2.8 SWOT Analysis
 7.3 ACELOT INC (US)
 7.4 CLOUD PHARMACEUTICALS INC. (US)
 7.5 DASSAULT SYSTEMES (FRANCE)
 7.6 IBM CORPORATION (US)
 7.7 SAS INSTITUTE INC. (THE US)
 7.8 TATA CONSULTANCY SERVICES LTD. (INDIA)
 7.9 WUXI APPTEC (CHINA)
 7.10 COLLABORATIVE DRUG DISCOVERY (CDD)
 7.11 SCYNEXIS INC. (THE US)
 7.12 MEDIDATA (US)
 7.13 CERTARA (US)
 7.14 GOOGLE (US)
 7.15 CLOUDPHARM
 7.16 AMAZON WEB SERVICES INC. (THE US)
 7.17 OTHERS

Chapter 8: Global Cloud-Based Drug Discovery Platforms Market Analysis, Insights and Forecast, 2016-2028
 8.1 Market Overview
 8.2 Historic and Forecasted Market Size By Type
  8.2.1 Infrastructure as a Service {IaaS}
  8.2.2 Software as a Service {SaaS}
  8.2.3 Platform as a Service {PaaS}
 8.3 Historic and Forecasted Market Size By Deployment Mode
  8.3.1 Public
  8.3.2 Private
  8.3.3 Hybrid
 8.4 Historic and Forecasted Market Size By End User
  8.4.1 Pharmaceutical Vendors
  8.4.2 Biotech Vendors
  8.4.3 Contract Research Organizations
  8.4.4 Others

Chapter 9: North America Cloud-Based Drug Discovery Platforms Market Analysis, Insights and Forecast, 2016-2028
 9.1 Key Market Trends, Growth Factors and Opportunities
 9.2 Impact of Covid-19
 9.3 Key Players
 9.4 Key Market Trends, Growth Factors and Opportunities
 9.4 Historic and Forecasted Market Size By Type
  9.4.1 Infrastructure as a Service {IaaS}
  9.4.2 Software as a Service {SaaS}
  9.4.3 Platform as a Service {PaaS}
 9.5 Historic and Forecasted Market Size By Deployment Mode
  9.5.1 Public
  9.5.2 Private
  9.5.3 Hybrid
 9.6 Historic and Forecasted Market Size By End User
  9.6.1 Pharmaceutical Vendors
  9.6.2 Biotech Vendors
  9.6.3 Contract Research Organizations
  9.6.4 Others
 9.7 Historic and Forecast Market Size by Country
  9.7.1 U.S.
  9.7.2 Canada
  9.7.3 Mexico

Chapter 10: Europe Cloud-Based Drug Discovery Platforms Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Type
  10.4.1 Infrastructure as a Service {IaaS}
  10.4.2 Software as a Service {SaaS}
  10.4.3 Platform as a Service {PaaS}
 10.5 Historic and Forecasted Market Size By Deployment Mode
  10.5.1 Public
  10.5.2 Private
  10.5.3 Hybrid
 10.6 Historic and Forecasted Market Size By End User
  10.6.1 Pharmaceutical Vendors
  10.6.2 Biotech Vendors
  10.6.3 Contract Research Organizations
  10.6.4 Others
 10.7 Historic and Forecast Market Size by Country
  10.7.1 Germany
  10.7.2 U.K.
  10.7.3 France
  10.7.4 Italy
  10.7.5 Russia
  10.7.6 Spain

Chapter 11: Asia-Pacific Cloud-Based Drug Discovery Platforms Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Type
  11.4.1 Infrastructure as a Service {IaaS}
  11.4.2 Software as a Service {SaaS}
  11.4.3 Platform as a Service {PaaS}
 11.5 Historic and Forecasted Market Size By Deployment Mode
  11.5.1 Public
  11.5.2 Private
  11.5.3 Hybrid
 11.6 Historic and Forecasted Market Size By End User
  11.6.1 Pharmaceutical Vendors
  11.6.2 Biotech Vendors
  11.6.3 Contract Research Organizations
  11.6.4 Others
 11.7 Historic and Forecast Market Size by Country
  11.7.1 China
  11.7.2 India
  11.7.3 Japan
  11.7.4 Southeast Asia

Chapter 12: South America Cloud-Based Drug Discovery Platforms Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Type
  12.4.1 Infrastructure as a Service {IaaS}
  12.4.2 Software as a Service {SaaS}
  12.4.3 Platform as a Service {PaaS}
 12.5 Historic and Forecasted Market Size By Deployment Mode
  12.5.1 Public
  12.5.2 Private
  12.5.3 Hybrid
 12.6 Historic and Forecasted Market Size By End User
  12.6.1 Pharmaceutical Vendors
  12.6.2 Biotech Vendors
  12.6.3 Contract Research Organizations
  12.6.4 Others
 12.7 Historic and Forecast Market Size by Country
  12.7.1 Brazil
  12.7.2 Argentina

Chapter 13: Middle East & Africa Cloud-Based Drug Discovery Platforms Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Type
  13.4.1 Infrastructure as a Service {IaaS}
  13.4.2 Software as a Service {SaaS}
  13.4.3 Platform as a Service {PaaS}
 13.5 Historic and Forecasted Market Size By Deployment Mode
  13.5.1 Public
  13.5.2 Private
  13.5.3 Hybrid
 13.6 Historic and Forecasted Market Size By End User
  13.6.1 Pharmaceutical Vendors
  13.6.2 Biotech Vendors
  13.6.3 Contract Research Organizations
  13.6.4 Others
 13.7 Historic and Forecast Market Size by Country
  13.7.1 Saudi Arabia
  13.7.2 South Africa

Chapter 14 Investment Analysis

Chapter 15 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET COMPETITIVE RIVALRY
TABLE 005. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET THREAT OF NEW ENTRANTS
TABLE 006. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET THREAT OF SUBSTITUTES
TABLE 007. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET BY TYPE
TABLE 008. INFRASTRUCTURE AS A SERVICE {IAAS} MARKET OVERVIEW (2016-2028)
TABLE 009. SOFTWARE AS A SERVICE {SAAS} MARKET OVERVIEW (2016-2028)
TABLE 010. PLATFORM AS A SERVICE {PAAS} MARKET OVERVIEW (2016-2028)
TABLE 011. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET BY DEPLOYMENT MODE
TABLE 012. PUBLIC MARKET OVERVIEW (2016-2028)
TABLE 013. PRIVATE MARKET OVERVIEW (2016-2028)
TABLE 014. HYBRID MARKET OVERVIEW (2016-2028)
TABLE 015. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET BY END USER
TABLE 016. PHARMACEUTICAL VENDORS MARKET OVERVIEW (2016-2028)
TABLE 017. BIOTECH VENDORS MARKET OVERVIEW (2016-2028)
TABLE 018. CONTRACT RESEARCH ORGANIZATIONS MARKET OVERVIEW (2016-2028)
TABLE 019. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 020. NORTH AMERICA CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY TYPE (2016-2028)
TABLE 021. NORTH AMERICA CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY DEPLOYMENT MODE (2016-2028)
TABLE 022. NORTH AMERICA CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY END USER (2016-2028)
TABLE 023. N CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY COUNTRY (2016-2028)
TABLE 024. EUROPE CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY TYPE (2016-2028)
TABLE 025. EUROPE CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY DEPLOYMENT MODE (2016-2028)
TABLE 026. EUROPE CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY END USER (2016-2028)
TABLE 027. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY COUNTRY (2016-2028)
TABLE 028. ASIA PACIFIC CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY TYPE (2016-2028)
TABLE 029. ASIA PACIFIC CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY DEPLOYMENT MODE (2016-2028)
TABLE 030. ASIA PACIFIC CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY END USER (2016-2028)
TABLE 031. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY COUNTRY (2016-2028)
TABLE 032. MIDDLE EAST & AFRICA CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY TYPE (2016-2028)
TABLE 033. MIDDLE EAST & AFRICA CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY DEPLOYMENT MODE (2016-2028)
TABLE 034. MIDDLE EAST & AFRICA CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY END USER (2016-2028)
TABLE 035. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY COUNTRY (2016-2028)
TABLE 036. SOUTH AMERICA CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY TYPE (2016-2028)
TABLE 037. SOUTH AMERICA CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY DEPLOYMENT MODE (2016-2028)
TABLE 038. SOUTH AMERICA CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY END USER (2016-2028)
TABLE 039. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET, BY COUNTRY (2016-2028)
TABLE 040. ACCENTURE PLC (IRELAND): SNAPSHOT
TABLE 041. ACCENTURE PLC (IRELAND): BUSINESS PERFORMANCE
TABLE 042. ACCENTURE PLC (IRELAND): PRODUCT PORTFOLIO
TABLE 043. ACCENTURE PLC (IRELAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. ACELOT INC (US): SNAPSHOT
TABLE 044. ACELOT INC (US): BUSINESS PERFORMANCE
TABLE 045. ACELOT INC (US): PRODUCT PORTFOLIO
TABLE 046. ACELOT INC (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. CLOUD PHARMACEUTICALS INC. (US): SNAPSHOT
TABLE 047. CLOUD PHARMACEUTICALS INC. (US): BUSINESS PERFORMANCE
TABLE 048. CLOUD PHARMACEUTICALS INC. (US): PRODUCT PORTFOLIO
TABLE 049. CLOUD PHARMACEUTICALS INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. DASSAULT SYSTEMES (FRANCE): SNAPSHOT
TABLE 050. DASSAULT SYSTEMES (FRANCE): BUSINESS PERFORMANCE
TABLE 051. DASSAULT SYSTEMES (FRANCE): PRODUCT PORTFOLIO
TABLE 052. DASSAULT SYSTEMES (FRANCE): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. IBM CORPORATION (US): SNAPSHOT
TABLE 053. IBM CORPORATION (US): BUSINESS PERFORMANCE
TABLE 054. IBM CORPORATION (US): PRODUCT PORTFOLIO
TABLE 055. IBM CORPORATION (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. SAS INSTITUTE INC. (THE US): SNAPSHOT
TABLE 056. SAS INSTITUTE INC. (THE US): BUSINESS PERFORMANCE
TABLE 057. SAS INSTITUTE INC. (THE US): PRODUCT PORTFOLIO
TABLE 058. SAS INSTITUTE INC. (THE US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. TATA CONSULTANCY SERVICES LTD. (INDIA): SNAPSHOT
TABLE 059. TATA CONSULTANCY SERVICES LTD. (INDIA): BUSINESS PERFORMANCE
TABLE 060. TATA CONSULTANCY SERVICES LTD. (INDIA): PRODUCT PORTFOLIO
TABLE 061. TATA CONSULTANCY SERVICES LTD. (INDIA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. WUXI APPTEC (CHINA): SNAPSHOT
TABLE 062. WUXI APPTEC (CHINA): BUSINESS PERFORMANCE
TABLE 063. WUXI APPTEC (CHINA): PRODUCT PORTFOLIO
TABLE 064. WUXI APPTEC (CHINA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. COLLABORATIVE DRUG DISCOVERY (CDD): SNAPSHOT
TABLE 065. COLLABORATIVE DRUG DISCOVERY (CDD): BUSINESS PERFORMANCE
TABLE 066. COLLABORATIVE DRUG DISCOVERY (CDD): PRODUCT PORTFOLIO
TABLE 067. COLLABORATIVE DRUG DISCOVERY (CDD): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. SCYNEXIS INC. (THE US): SNAPSHOT
TABLE 068. SCYNEXIS INC. (THE US): BUSINESS PERFORMANCE
TABLE 069. SCYNEXIS INC. (THE US): PRODUCT PORTFOLIO
TABLE 070. SCYNEXIS INC. (THE US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. MEDIDATA (US): SNAPSHOT
TABLE 071. MEDIDATA (US): BUSINESS PERFORMANCE
TABLE 072. MEDIDATA (US): PRODUCT PORTFOLIO
TABLE 073. MEDIDATA (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. CERTARA (US): SNAPSHOT
TABLE 074. CERTARA (US): BUSINESS PERFORMANCE
TABLE 075. CERTARA (US): PRODUCT PORTFOLIO
TABLE 076. CERTARA (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 076. GOOGLE (US): SNAPSHOT
TABLE 077. GOOGLE (US): BUSINESS PERFORMANCE
TABLE 078. GOOGLE (US): PRODUCT PORTFOLIO
TABLE 079. GOOGLE (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 079. CLOUDPHARM: SNAPSHOT
TABLE 080. CLOUDPHARM: BUSINESS PERFORMANCE
TABLE 081. CLOUDPHARM: PRODUCT PORTFOLIO
TABLE 082. CLOUDPHARM: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 082. AMAZON WEB SERVICES INC. (THE US): SNAPSHOT
TABLE 083. AMAZON WEB SERVICES INC. (THE US): BUSINESS PERFORMANCE
TABLE 084. AMAZON WEB SERVICES INC. (THE US): PRODUCT PORTFOLIO
TABLE 085. AMAZON WEB SERVICES INC. (THE US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 085. OTHERS: SNAPSHOT
TABLE 086. OTHERS: BUSINESS PERFORMANCE
TABLE 087. OTHERS: PRODUCT PORTFOLIO
TABLE 088. OTHERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET OVERVIEW BY TYPE
FIGURE 012. INFRASTRUCTURE AS A SERVICE {IAAS} MARKET OVERVIEW (2016-2028)
FIGURE 013. SOFTWARE AS A SERVICE {SAAS} MARKET OVERVIEW (2016-2028)
FIGURE 014. PLATFORM AS A SERVICE {PAAS} MARKET OVERVIEW (2016-2028)
FIGURE 015. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET OVERVIEW BY DEPLOYMENT MODE
FIGURE 016. PUBLIC MARKET OVERVIEW (2016-2028)
FIGURE 017. PRIVATE MARKET OVERVIEW (2016-2028)
FIGURE 018. HYBRID MARKET OVERVIEW (2016-2028)
FIGURE 019. CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET OVERVIEW BY END USER
FIGURE 020. PHARMACEUTICAL VENDORS MARKET OVERVIEW (2016-2028)
FIGURE 021. BIOTECH VENDORS MARKET OVERVIEW (2016-2028)
FIGURE 022. CONTRACT RESEARCH ORGANIZATIONS MARKET OVERVIEW (2016-2028)
FIGURE 023. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 024. NORTH AMERICA CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 025. EUROPE CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. ASIA PACIFIC CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. MIDDLE EAST & AFRICA CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. SOUTH AMERICA CLOUD-BASED DRUG DISCOVERY PLATFORMS MARKET OVERVIEW BY COUNTRY (2016-2028)